Table 5.

Combining response rate with PFS in evaluating chemotherapy.

Year	Chemotherapy regimen	RR (%)	PFS	OS
Category A: both RR and PFS above average (n=9)
2006	gemcitabine + epirubicin13	43.3	8
2008	pegylated liposomal doxorubicin (biweekly)24	40	4.1	16.5
2008	gemcitabine + pegylated liposomal doxorubicin14	37.5	6.9	18.2
2009	gemcitabine + oxaliplatin17	37	4.6	11.4
2007	gemcitabine + cisplatin (biweekly)19	31.5	4.9	13.2
2006	topotecan + pegylated liposomal doxorubicin26	28	7.5	10.3
2006	pegylated liposomal doxorubicin25	23.1	5.4	13.8
2005	docetaxel + irinotecan69	20	5	11
2006	gemcitabine + cisplatin20	16	5.4	14.9
Category B: RR above average but PFS below average (n=4)
2006	gemcitabine + pegylated liposomal doxorubicin15	33.3	3.8	15.8
2005	gemcitabine + pegylated liposomal doxorubicin16	22	2.7	8.4
2009	pemetrexed55	21	2.9	11.4
2008	gemcitabine + topotecan21	17	3	12.6
Category C: RR below average but PFS above average (n=6)
2007	bevacizumab50	15.9	4.4	10.7
2005	canfosfamide 70	15	7.2	14.1
2010	ixabepilone53	14.3	4.4	14.8
2006	LY355703 (cryptophycin analog)57	12.5	5.1
2007	gemcitabine + oxaliplatin18	9.5	5	9.2
2005	sabarubicin73	5.3	4.2	2.1
Category D: both RR and PFS below average (n=10)
2005	9-aminocamptothecin54	14	2.9	10
2009	pemetrexed56	9.9	2.8	11.1
2008	topotecan + pegylated liposomal doxorubicin27	9.1	2	10.5
2007	pegylated liposomal doxorubicin†,12	8.3	3.1	13.5
2007	gemcitabine†,12	6.1	3.6	12.7
2009	canfosfamide74	4.3	2.3	13.5
2009	capecitabine75	3.1	2.3
2007	tamoxifen + gefitinib60	0	1.9	8.4
2007	docetaxel (weekly)44	0	3.1	12.3
2007	matuzumab79	0	1.8	13.3

Total 29 clinical trials that both response rate and PFS were available were classified into 4 groups based on the cutoff values of overall response rate (16%) and PFS (4.1 months) among clinical trials.

Abbreviations: RR, response rate; PFS, median progression-free survival (months); and OS, median overall survival (months).